- Home
- QSI vs YMAB Comparison
QSI vs YMAB Comparison
Compare QSI & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- YMAB
- Stock Information
- Founded
- QSI 2013
- YMAB 2015
- Country
- QSI United States
- YMAB United States
- Employees
- QSI N/A
- YMAB N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- YMAB Health Care
- Exchange
- QSI Nasdaq
- YMAB Nasdaq
- Market Cap
- QSI 288.2M
- YMAB 270.5M
- IPO Year
- QSI N/A
- YMAB 2018
- Fundamental
- Price
- QSI $1.71
- YMAB $5.72
- Analyst Decision
- QSI Strong Buy
- YMAB Strong Buy
- Analyst Count
- QSI 3
- YMAB 10
- Target Price
- QSI $3.42
- YMAB $21.10
- AVG Volume (30 Days)
- QSI 10.1M
- YMAB 542.6K
- Earning Date
- QSI 03-03-2025
- YMAB 03-04-2025
- Dividend Yield
- QSI N/A
- YMAB N/A
- EPS Growth
- QSI N/A
- YMAB N/A
- EPS
- QSI N/A
- YMAB N/A
- Revenue
- QSI $2,266,000.00
- YMAB $84,553,000.00
- Revenue This Year
- QSI $193.90
- YMAB $6.41
- Revenue Next Year
- QSI $173.18
- YMAB $18.15
- P/E Ratio
- QSI N/A
- YMAB N/A
- Revenue Growth
- QSI 232.26
- YMAB N/A
- 52 Week Low
- QSI $0.61
- YMAB $5.60
- 52 Week High
- QSI $5.77
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- QSI 39.90
- YMAB 35.08
- Support Level
- QSI $1.82
- YMAB $5.60
- Resistance Level
- QSI $2.10
- YMAB $6.57
- Average True Range (ATR)
- QSI 0.17
- YMAB 0.38
- MACD
- QSI -0.02
- YMAB 0.10
- Stochastic Oscillator
- QSI -0.93
- YMAB 11.43
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.